Overview

Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects

Status:
Completed
Trial end date:
2010-06-26
Target enrollment:
Participant gender:
Summary
This was a single-center, double-blind, randomized, active control, single dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) profiles of P1101 in 48 healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
PharmaEssentia
Treatments:
Peginterferon alfa-2a